行情

FPRX

FPRX

Five Prime
NASDAQ

实时行情|Nasdaq Last Sale

2.120
+0.120
+6.00%
交易中 15:49 04/02 EDT
开盘
2.010
昨收
2.000
最高
2.120
最低
1.950
成交量
12.43万
成交额
--
52周最高
13.80
52周最低
1.750
市值
7,715.10万
市盈率(TTM)
-0.5402
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测FPRX价格均价为8.00,最高价位11.00,最低价为5.00。

EPS

FPRX 新闻

更多
  • Edited Transcript of FPRX earnings conference call or presentation 27-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/18 22:54
  • Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
  • Business Wire · 03/13 14:25
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37
  • The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
  • Benzinga · 03/11 12:05

所属板块

生物技术和医学研究
+1.84%
制药与医学研究
+1.79%

热门股票

代码
价格
涨跌幅

FPRX 简况

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.
展开

微牛提供Five Prime Therapeutics Inc(NASDAQ-FPRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的FPRX股票新闻,以帮助您做出投资决策。